AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🌍 Showing

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Condition

Country

City (shown first)

30 recruiting trials

for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients NCT07313592n/a1 site📍 St Louis Washington University School of Medicine Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site📍 Madison University of Wisconsin, Madison · Tests: TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) NCT04301076Phase 119 sites📍 Atlanta📍 Atlanta📍 City of Saint Peters National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites📍 Beijing📍 Beijing📍 Chongqing Chongqing Precision Biotech Co., Ltd · Tests: pCAR-19B cells A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma NCT07075328Phase 1, Phase 25 sites📍 Fukuoka📍 Sapporo📍 Kagoshima Otsuka Medical Devices Co., Ltd. Japan · Tests: Drug:5-ALA, Device:Photodynamic system CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site📍 Riyadh King Faisal Specialist Hospital & Research Center · Tests: CAR T cells chimeric antigen receptor cells Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site📍 Beijing Peking University People's Hospital · Tests: Senl_B19 autologous CAR-T (S1904) treatment A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) NCT06561074Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine, Venetoclax, Calaspargase pegol-mknl Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma NCT07300683Phase 11 site📍 London University College, London · Tests: CARCCR9 T cells A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506Phase 1, Phase 29 sites📍 Hefei📍 Chongqing📍 Guangzhou Juventas Cell Therapy Ltd. · Tests: single dose of CNCT19 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites📍 Los Angeles📍 Palo Alto📍 Aurora Autolus Limited · Tests: AUTO1 A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites📍 Tübingen📍 Tübingen University Hospital Tuebingen · Tests: CAR-T cells targeting CD19 and CD22 Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies NCT07584889Phase 1, Phase 21 site📍 Shenzhen Shenzhen University General Hospital · Tests: CAR-T cell Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells NCT06420076Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD5/CD7 CAR-T Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT07008885Phase 1, Phase 22 sites📍 Beijing📍 Beijing Chinese PLA General Hospital · Tests: CAR19TIF cells, Fludarabine, Cyclophosphamide A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy NCT04227015EARLY Phase 11 site📍 Hangzhou He Huang · Tests: CTA101 Determining the Mechanisms of Loss of CAR T Cell Persistence NCT05809284n/a3 sites📍 London📍 London📍 Manchester University College, London CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. NCT06752785Phase 11 site📍 Guangzhou Guangzhou Women and Children's Medical Center · Tests: CAR-T Therapy Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL NCT06880913Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma NCT06934382Phase 11 site📍 Philadelphia Stephan Grupp MD PhD · Tests: Allogeneic anti-CD7 CAR-T cells (BEAM-201) Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CAR-T cells, Venetoclax, Olverembatinib Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites📍 Beijing📍 Shanghai📍 Shanghai Beijing GoBroad Hospital · Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies NCT06909474Phase 11 site📍 Wuhan Chongqing Precision Biotech Co., Ltd · Tests: Anti-CD5 CAR NK cells A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies NCT04532281EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: Murine CD19 CAR-T cells Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735Phase 1, Phase 26 sites📍 Beijing📍 Beijing📍 Beijing Chinese PLA General Hospital · Tests: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia NCT02443831Phase 13 sites📍 London📍 London📍 Manchester University College, London · Tests: Leukapheresis, Total Body Irradiation (TBI), Lymphodepletion with Fludarabine, Lymphodepletion with Cyclophosphamide, C… Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites📍 Vienna📍 Ghent📍 Copenhagen Princess Maxima Center for Pediatric Oncology · Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy

🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy